The Prognostic Impacts of PABPC1 Expression on Gastric Cancer Patients

Citations Over TimeTop 16% of 2021 papers

Abstract

Aim: To assess the prognostic impacts of PABPC1 on gastric cancer (GC) patients. Methods: The expression levels of PABPC1 in GC tissues and normal gastric tissues were initially compared via bioinformatics analysis. Immunohistochemical staining was accomplished to assess the expression of PABPC1 in the included GC patients. Then the impacts of PABPC1 expression on survival of GC patients were evaluated by Cox regression and Kaplan-Meier analyses. Results: The expression levels of PABPC1 in gastric tissues were significantly higher than those in normal gastric tissues (paired, p = 0.002; unpaired, p = 3.60e-9). By Kaplan-Meier, it was demonstrated that high expression of PABPC1 was significantly associated with worse overall and disease-free survival. Furthermore, high PABPC1 expression was demonstrated to be an independent predictive factor for both overall (p = 0.013; hazard ratio = 2.058; 95% CI: 1.162-3.644) and disease-free (p = 0.018; hazard ratio = 2.284; 95% CI: 1.153-4.524) survival. Conclusion: PABPC1 is a potential prognostic biomarker for GC patients.

Related Papers

• → Resonance Raman spectroscopic evaluation of skin carotenoids as a biomarker of carotenoid status for human studies(2013)110 cited
• → Supporting evidence for using biomarkers in the diagnosis of MCI due to AD(2012)55 cited
• → P2‐215: Supporting evidence of the Alzheimer's disease biomarker dynamic model in patients with mild cognitive impairment(2012)1 cited
• → P.1.c.001 An ethopharmacological assessment of the effects of (R, S)-2-chloro-5-hydroxyphenylglycine (CHPG) on agonistic interactions in male mice(2008)
• → P4‐123: Resolving Conflicting CSF Biomarker Information in Alzheimer′s Disease(2016)